Pfizer Quick Ratio 2011-2025 | PFE
Historical quick ratio values for Pfizer (PFE) over the last 10 years.
| Pfizer Quick Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets - Inventory | Current Liabilities | Quick Ratio |
| 2025-09-30 | $35.46B | $36.60B | 0.97 |
| 2025-06-30 | $32.03B | $37.73B | 0.85 |
| 2025-03-31 | $35.01B | $36.45B | 0.96 |
| 2024-12-31 | $39.51B | $43.00B | 0.92 |
| 2024-09-30 | $31.50B | $43.21B | 0.73 |
| 2024-06-30 | $26.38B | $43.82B | 0.60 |
| 2024-03-31 | $31.52B | $40.50B | 0.78 |
| 2023-12-31 | $33.14B | $47.79B | 0.69 |
| 2023-09-30 | $63.81B | $31.14B | 2.05 |
| 2023-06-30 | $63.04B | $34.65B | 1.82 |
| 2023-03-31 | $40.54B | $36.56B | 1.11 |
| 2022-12-31 | $42.28B | $42.14B | 1.00 |
| 2022-09-30 | $60.89B | $44.31B | 1.37 |
| 2022-06-30 | $57.01B | $47.41B | 1.20 |
| 2022-03-31 | $44.44B | $39.27B | 1.13 |
| 2021-12-31 | $50.63B | $42.67B | 1.19 |
| 2021-09-30 | $49.26B | $41.80B | 1.18 |
| 2021-06-30 | $39.87B | $35.66B | 1.12 |
| 2021-03-31 | $31.04B | $26.65B | 1.17 |
| 2020-12-31 | $27.05B | $25.92B | 1.04 |
| 2020-09-30 | $38.44B | $34.15B | 1.13 |
| 2020-06-30 | $37.86B | $32.72B | 1.16 |
| 2020-03-31 | $26.32B | $33.89B | 0.78 |
| 2019-12-31 | $25.74B | $37.30B | 0.69 |
| 2019-09-30 | $25.24B | $36.97B | 0.68 |
| 2019-06-30 | $38.84B | $32.03B | 1.21 |
| 2019-03-31 | $37.26B | $29.42B | 1.27 |
| 2018-12-31 | $42.42B | $31.86B | 1.33 |
| 2018-09-30 | $33.40B | $29.01B | 1.15 |
| 2018-06-30 | $29.23B | $32.16B | 0.91 |
| 2018-03-31 | $26.69B | $27.37B | 0.98 |
| 2017-12-31 | $33.56B | $30.43B | 1.10 |
| 2017-09-30 | $32.37B | $28.22B | 1.15 |
| 2017-06-30 | $28.80B | $27.18B | 1.06 |
| 2017-03-31 | $28.46B | $24.86B | 1.15 |
| 2016-12-31 | $32.17B | $31.12B | 1.03 |
| 2016-09-30 | $30.99B | $34.76B | 0.89 |
| 2016-06-30 | $36.23B | $32.10B | 1.13 |
| 2016-03-31 | $33.72B | $28.74B | 1.17 |
| 2015-12-31 | $36.29B | $29.40B | 1.23 |
| 2015-09-30 | $37.32B | $27.85B | 1.34 |
| 2015-06-30 | $45.92B | $24.14B | 1.90 |
| 2015-03-31 | $43.66B | $20.22B | 2.16 |
| 2014-12-31 | $49.93B | $21.59B | 2.31 |
| 2014-09-30 | $50.63B | $19.92B | 2.54 |
| 2014-06-30 | $52.04B | $21.94B | 2.37 |
| 2014-03-31 | $51.73B | $24.79B | 2.09 |
| 2013-12-31 | $50.08B | $23.37B | 2.14 |
| 2013-09-30 | $53.02B | $20.37B | 2.60 |
| 2013-06-30 | $55.15B | $23.45B | 2.35 |
| 2013-03-31 | $57.73B | $27.54B | 2.10 |
| 2012-12-31 | $58.76B | $29.19B | 2.01 |
| 2012-09-30 | $49.61B | $29.13B | 1.70 |
| 2012-06-30 | $51.76B | $30.80B | 1.68 |
| 2012-03-31 | $47.67B | $27.09B | 1.76 |
| 2011-12-31 | $54.21B | $28.91B | 1.88 |
| 2011-09-30 | $54.31B | $27.86B | 1.95 |
| 2011-06-30 | $51.89B | $30.47B | 1.70 |
| 2011-03-31 | $49.78B | $29.17B | 1.71 |
| 2010-12-31 | $52.74B | $28.64B | 1.84 |
| 2010-09-30 | $45.32B | $24.17B | 1.88 |
| 2010-06-30 | $41.59B | $24.68B | 1.69 |
| 2010-03-31 | $39.78B | $25.92B | 1.54 |
| 2009-12-31 | $49.27B | $37.23B | 1.32 |
| 2009-09-30 | $68.73B | $23.99B | 2.87 |
| 2009-06-30 | $66.56B | $26.11B | 2.55 |
| 2009-03-31 | $49.80B | $23.34B | 2.13 |
| 2008-12-31 | $38.70B | $27.01B | 1.43 |
| 2008-09-30 | $43.44B | $21.50B | 2.02 |
| 2008-06-30 | $43.32B | $23.19B | 1.87 |
| 2008-03-31 | $45.86B | $21.68B | 2.12 |
| 2007-12-31 | $41.55B | $21.84B | 1.90 |
| 2007-09-30 | $36.63B | $14.33B | 2.56 |
| 2007-06-30 | $35.89B | $15.14B | 2.37 |
| 2007-03-31 | $36.64B | $13.30B | 2.76 |
| 2006-12-31 | $41.55B | $22.10B | 1.88 |
| 2006-09-30 | $32.55B | $17.69B | 1.84 |
| 2006-06-30 | $34.60B | $20.06B | 1.73 |
| 2006-03-31 | $30.75B | $19.67B | 1.56 |
| 2005-12-31 | $41.36B | $28.40B | 1.46 |
| 2005-09-30 | $26.21B | $20.40B | 1.29 |
| 2005-06-30 | $27.09B | $22.57B | 1.20 |
| 2005-03-31 | $35.80B | $28.95B | 1.24 |
| 2004-12-31 | $32.43B | $26.46B | 1.23 |
| 2004-09-30 | $32.76B | $25.24B | 1.30 |
| 2004-06-30 | $30.82B | $25.16B | 1.23 |
| 2004-03-31 | $29.45B | $24.64B | 1.20 |
| 2003-12-31 | $24.98B | $23.91B | 1.05 |
| 2003-09-30 | $26.37B | $21.66B | 1.22 |
| 2003-06-30 | $28.01B | $22.16B | 1.26 |
| 2003-03-31 | $28.50B | $18.75B | 1.52 |
| 2002-12-31 | $22.10B | $18.56B | 1.19 |
| 2002-09-30 | $20.76B | $18.40B | 1.13 |
| 2002-06-30 | $19.58B | $16.32B | 1.20 |
| 2002-03-31 | $18.22B | $14.73B | 1.24 |
| 2001-12-31 | $16.73B | $13.73B | 1.22 |
| 2001-09-30 | $17.16B | $13.04B | 1.32 |
| 2001-06-30 | $16.67B | $11.98B | 1.39 |
| 2001-03-31 | $15.81B | $10.87B | 1.45 |
| 2000-12-31 | $14.49B | $11.98B | 1.21 |
| 2000-09-30 | $14.45B | $12.34B | 1.17 |
| 2000-06-30 | $13.22B | $12.22B | 1.08 |
| 2000-03-31 | $8.82B | $7.48B | 1.18 |
| 1999-12-31 | $9.54B | $9.19B | 1.04 |
| 1999-09-30 | $9.85B | $9.09B | 1.08 |
| 1999-06-30 | $9.35B | $8.81B | 1.06 |
| 1999-03-31 | $9.05B | $7.75B | 1.17 |
| 1998-12-31 | $8.10B | $7.19B | 1.13 |
| 1998-09-30 | $8.19B | $7.26B | 1.13 |
| 1998-06-30 | $6.42B | $6.14B | 1.05 |
| 1998-03-31 | $5.57B | $5.68B | 0.98 |
| 1997-12-31 | $5.05B | $5.31B | 0.95 |
| 1997-09-30 | $5.42B | $5.78B | 0.94 |
| 1997-06-30 | $5.68B | $6.42B | 0.88 |
| 1997-03-31 | $5.33B | $5.78B | 0.92 |
| 1996-12-31 | $4.88B | $5.64B | 0.87 |
| 1996-09-30 | $5.19B | $6.20B | 0.84 |
| 1996-06-30 | $5.05B | $5.85B | 0.86 |
| 1996-03-31 | $4.90B | $5.48B | 0.90 |
| 1995-12-31 | $4.77B | $5.19B | 0.92 |
| 1995-09-30 | $4.79B | $5.80B | 0.83 |
| 1995-06-30 | $4.52B | $6.10B | 0.74 |
| 1995-03-31 | $4.42B | $5.78B | 0.77 |
| 1994-12-31 | $4.52B | $4.83B | 0.94 |
| 1994-09-30 | $4.16B | $4.14B | 1.01 |
| 1994-06-30 | $3.93B | $4.29B | 0.92 |
| 1994-03-31 | $3.77B | $3.75B | 1.01 |
| 1993-12-31 | $3.64B | $3.44B | 1.06 |
| 1993-09-30 | $4.57B | $4.15B | 1.10 |
| 1993-06-30 | $4.56B | $4.10B | 1.11 |
| 1993-03-31 | $4.33B | $3.62B | 1.20 |
| 1992-12-31 | $4.32B | $3.22B | 1.34 |
| 1992-09-30 | $4.41B | $3.22B | 1.37 |
| 1992-06-30 | $3.84B | $3.16B | 1.22 |
| 1992-03-31 | $3.54B | $3.05B | 1.16 |
| 1991-12-31 | $3.64B | $3.42B | 1.06 |
| 1991-09-30 | $3.17B | $3.23B | 0.98 |
| 1991-06-30 | $3.16B | $3.26B | 0.97 |
| 1991-03-31 | $3.08B | $2.83B | 1.09 |
| 1990-12-31 | $3.29B | $3.12B | 1.06 |
| 1990-09-30 | $2.67B | $2.68B | 1.00 |
| 1990-06-30 | $2.79B | $2.58B | 1.08 |
| 1990-03-31 | $2.92B | $2.35B | 1.24 |
| 1989-12-31 | $3.42B | $2.91B | 1.18 |
| 1989-09-30 | $2.72B | $2.32B | 1.17 |
| 1989-06-30 | $2.68B | $2.43B | 1.10 |
| 1989-03-31 | $2.98B | $2.16B | 1.38 |
| 1988-12-31 | $3.01B | $2.34B | 1.28 |
| 1988-09-30 | $2.94B | $2.05B | 1.44 |
| 1988-06-30 | $2.99B | $2.05B | 1.46 |
| 1988-03-31 | $3.04B | $1.87B | 1.62 |
| 1987-12-31 | $3.07B | $1.96B | 1.57 |
| 1987-09-30 | $1.75B | $1.49B | 1.18 |
| 1987-06-30 | $1.65B | $1.49B | 1.11 |
| 1987-03-31 | $1.50B | $1.22B | 1.22 |
| 1986-12-31 | $2.07B | $1.23B | 1.68 |
| 1985-12-31 | $1.36B | $0.96B | 1.41 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $146.634B | $63.627B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $967.005B | 46.51 |
| Johnson & Johnson (JNJ) | United States | $470.415B | 18.81 |
| AbbVie (ABBV) | United States | $410.546B | 24.58 |
| Roche Holding AG (RHHBY) | Switzerland | $289.653B | 0.00 |
| Novartis AG (NVS) | Switzerland | $278.650B | 14.77 |
| Merck (MRK) | United States | $230.654B | 10.74 |
| Novo Nordisk (NVO) | Denmark | $219.499B | 12.87 |
| Sanofi (SNY) | France | $128.522B | 12.34 |
| Bayer (BAYRY) | Germany | $33.795B | 5.93 |
| Innoviva (INVA) | United States | $1.660B | 8.31 |